PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Rifaximin in Pediatric Hepatic Encephalopathy: First Trial, Ammonia Miss

rifaximinrifamycin antibiotichepatic encephalopathyhyperammonemiapediatriccongenital portosystemic shuntopen-label trialpharmacokineticsgut microbiotaJapan Gastroenterology / Hepatology

Background Information

Rifaximin shows promise in pediatric hepatic encephalopathy treatment.

Hepatic encephalopathy (HE) significantly affects children's health, and rifaximin's role in treatment needs clear evaluation, especially regarding efficacy, safety, and dosage. Rifaximin treatment led to significant improvements in mental state and cognitive tests in pediatric patients with HE, but changes in blood ammonia concentration were not statistically significant. This study shows rifaximin's safety and efficacy profiles in children are comparable to adults, supporting its potential use in pediatric HE management. Rifaximin may improve mental state in children with hepatic encephalopathy, though biochemical changes are minimal.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Okajima H, Tagawa M, Fujisawa M, Ueda K

Citation: Okajima H, Tagawa M, Fujisawa M, et al. Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study. Hepatology communications. 2026;10(8). doi:10.1097/HC9.0000000000001002

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.